Earnings Call Summary | MAYNE PHARMA GROUP LIMITED(MAYNF.US) Q2 2024 Earnings Conference
Earnings Call Summary | MAYNE PHARMA GROUP LIMITED(MAYNF.US) Q2 2024 Earnings Conference
The following is a summary of the Mayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call Transcript:
以下是梅恩制药集团有限公司（MAYNF）2024年第二季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Mayne Pharma reported a gross profit of $105.8 million, reflecting a margin increase from 52% to 56%. Direct expenses were only up by 1% despite costs for growth and new products.
An underlying EBITDA of $8 million was reported, showing a significant improvement from the same period in the previous year.
Cash balance stands at $146.8 million, down from $220.1 million as of June.
The company achieved four out of five financial goals it set for itself for fiscal year 2024.
梅恩制药公布的毛利为1.058亿美元，利润率从52％增长到56％。尽管有增长和新产品的成本，但直接支出仅增长了1％。
报告的基础息税折旧摊销前利润为800万美元，与去年同期相比有显著改善。
现金余额为1.468亿美元，低于6月份的2.201亿美元。
该公司实现了自己为2024财年设定的五个财务目标中的四个。
Business Progress:
业务进展：
Women's Health saw a 45% increase in revenue, with a 96% increase in NEXTSTELLIS revenue specifically.
The company showed discipline in relation to channel liabilities, and new product launches have been significant.
Mayne Pharma remains focused on eliminating non-value adding costs and growing through differentiated products.
Positive trends in Dermatology and Women's Health business units greatly contributed to the overall growth.
The acquisition of RHOFADE for $8 million led to $8 million in revenue and $7.3 million margins in the first three months of ownership.
女性健康的收入增长了45％，特别是NEXTSTELLIS的收入增长了96％。
该公司在渠道负债方面表现出纪律，新产品的发布意义重大。
Mayne Pharma仍然专注于消除非增值成本，并通过差异化产品实现增长。
皮肤科和女性健康业务部门的积极趋势极大地促进了整体增长。
以800万美元收购RHOFADE在所有权的前三个月带来了800万美元的收入和730万美元的利润率。
More details: MAYNE PHARMA GROUP LIMITED IR
更多详情： 梅恩制药集团有限公司
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。